Search
TScan Therapeutics Inc
TCRXAdd to Watchlist
0.743USD
-0.013-1.68%
Close 07-31 16:00（ET）Quotes delayed by 15 min
42.28MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of TScan Therapeutics Inc is 7.71, ranking 273 out of 385 in the Biotechnology & Medical Research industry. The average price target is 6.00, with a high of 12.00 and a low of 4.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
6.000
Target Price
+709.06%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
TScan Therapeutics Inc
TCRX
7
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is TScan Therapeutics Inc's expected revenue for the next quarter?
TScan Therapeutics Inc's expected revenue is 1.67M.
What is TScan Therapeutics Inc's price target?
Analysts forecast that TScan Therapeutics Inc's price target is USD 6.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 4.00.
How have TScan Therapeutics IncTCRX's recent earnings per share performed?
The market expectation was USD -0.22, while TScan Therapeutics IncTCRX's earnings per share (EPS) for the previous quarter was USD -0.18. EPS for the next quarter is expected at USD -0.21.
What is the analyst rating for TScan Therapeutics Inc?
Based on the ratings of TScan Therapeutics Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.